| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Research and development contract liabilities | 77 | 21,069 |
| Advances on research and development contract services | - | 0 |
| Net cash used in operating activities | -1,982,720 | -1,055,968 |
| Purchase of digital assets | 2,637,360 | - |
| Net cash used in investing activities | -2,637,360 | - |
| Proceeds from sale of securities in registered direct offerings, net of offering costs | 2,245,040 | 914,228 |
| Proceeds from sale of securities in registered private placement, net of offering costs | 4,178,162 | - |
| Payment of deferred offering costs | - | 10,000 |
| Exercise of common stock warrants | 45,800 | - |
| Net cash provided by financing activities | 6,469,002 | 904,228 |
| Net increase (decrease) | 1,848,922 | -151,740 |
| Cash and cash equivalents at beginning of period | 1,038,952 | - |
| Cash and cash equivalents at end of period | 2,887,874 | - |
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)